Roquette expands plant-based excipient portfolio with Crest Cellulose acquisition
Crest Cellulose, an Indian excipient manufacturer, has been acquired by plant-based pharmaceutical excipient provider Roquette in a bid to increase the latter’s presence in the Asia Pacific region.
French provider of plant-based ingredients and pharmaceutical/nutraceutical excipients Roquette has announced their complete acquisition of Indian excipient manufacturer Crest Cellulose, expanding their capacity to meet global demand for plant-based excipients.
India’s pharmaceutical industry is one of the largest global providers of generic medicines at a time when the production of generics in the Asia Pacific region is increasing in general. The acquisition of Crest Cellulose is hoped to establish a reinforced presence for Roquette in India and Asia, while also providing a global network of pharmaceutical research, development, and innovation facilities.
Crest Cellulose is set to be smoothly integrated into Roquette’s existing rigorous quality standards, meeting all major international regulatory requirements for excipients produced at the facility. Such plant-based excipients include MICROCEL, a microcrystalline cellulose, and LYCATAB CT, a partially pregelatinized starch.
VP Roquette Pharma Solutions Paul Smaltz commented on the acquisition: “At Roquette, we believe true innovation can only be achieved in an environment where ingredient safety is completely assured... There’s no room for compromise or shortcuts when tackling the world’s greatest health challenges. The team at Crest Cellulose share our conviction that quality is king, always striving to optimize processes and redefine what’s possible in drug delivery. As a global leader in health and nutrition, we’re excited to harness our newly expanded capabilities to support our network of customers and partners in India, Asia, and the rest of the world.
The acquisition will also focus on protecting the health of the planet and sustainable practices, a core pillar of Roquette’s ethos in bringing about healthier futures. Crest Cellulose will become the latest recipient of the Greentech ‘Environmental Protection’ award, recognising the environmental efforts of companies respecting the planet and its natural resources. Smaltz added: “Adding Crest Cellulose to the Roquette family gives us an opportunity to expand the reach of our sustainable development initiatives underpinned by four key pillars – innovating, sourcing, biorefining, acting – to build a healthier tomorrow. For Crest Cellulose and its customers, this means sustainable development will become central to every operation – ensuring we deliver top quality solutions that champion people, the planet, and prosperity. Supporting our commitment to reducing greenhouse gas emissions by 25% between 2021 and 2030, plans are in motion to install an additional 0.5 megawatt solar panel to the 10 kilowatts already in place at the site. This investment is designed to provide renewable energy for decades to come.”
Source: Roquette Complete Acquisition of Crest Cellulose - Corporate Pharma| Roquette
Related News
-
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers. -
News MedPharm and Mosanna collaboration to develop novel Metabolic Obstructive Sleep Apnea treatment
A collaboration between development and manufacturing services company MedPharm and biotech company Mosanna aims to develop and deliver a nasal spray treatment for a form of sleep apnea. -
News Partnership between Bora Pharmaceuticals and TaiRx, Inc. for anticancer drug manufacturing
A partnership between Bora Pharmaceuticals and TaiRx, Inc. is expected to support the manufacturing of breakthrough anticancer drug CVM-1118, with two phase II clinical trials to commence. -
News Expansion of Quotient Sciences' UK drug development and manufacturing facilities
Quotient Sciences’ Nottingham and Reading facilities have announced the completion of their facility expansions, providing further capabilities to support their flagship program Translational Pharmaceutics®. -
News The Korean biopharma market: Incentivizing innovation
With new drug approvals hitting a record high in 2021 and unprecedented number of out-licensing deals closed in 2020, Korean pharmaceutical companies and CDMO’s are poised for significant market growth [i]. -
News Biden's $2 billion Biotech Boost
President Biden issues executive order to bolster U.S. biomanufacturing sector. -
News Phase III trials of Pfizer’s mRNA-based influenza vaccine begin
Leveraging their current mRNA vaccine technology developed during the COVID-19 pandemic, Pfizer have announced the start of phase III trials for a potential mRNA-based influenza vaccine.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance